嵌合抗原受体T细胞疗法在神经病学中的当前与未来作用:一篇综述
本综述概述了嵌合抗原受体(CAR)T细胞疗法在神经病学中的应用,重点涉及原发性脑肿瘤和自身免疫性神经系统疾病。胶质母细胞瘤的首次人体试验未取得显著成功或仅部分患者有限成功;在多发性硬化动物模型中有效但尚缺大规模人类研究验证;对复发或难治性水通道蛋白4-IgG阳性视神经脊髓炎谱系疾病及全身型肌无力患者显示疗效;嵌合自身抗体受体T细胞在体外和体内选择性靶向自身反应性抗N-甲基-D-天冬氨酸B细胞。
要点
- CAR T细胞治疗胶质母细胞瘤的首次人体试验未显著成功或仅部分患者有限成功。
- CAR T细胞对复发或难治性AQP4-IgG阳性视神经脊髓炎谱系疾病及全身型肌无力显示疗效。
- 嵌合自身抗体受体T细胞在体外和体内选择性靶向自身反应性抗NMDAR B细胞。
核心结论
- CAR T细胞开启了神经系统疾病治疗的新时代,在实体瘤中未普遍取得稳健成功,但新兴创新策略显示前景,对某些自身免疫性神经系统疾病的有效性持乐观态度。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 胶质母细胞瘤的CAR T细胞治疗首次人体试验未取得显著成功或仅部分患者有限成功。
- CAR T细胞疗法在多发性硬化动物模型中显示疗效,但尚需更大规模人类研究证实。
- CAR T细胞对复发或难治性水通道蛋白4-免疫球蛋白G血清阳性视神经脊髓炎谱系疾病患者显示疗效,需更大患者群体研究确认。
- 使用CAR T细胞治疗全身型肌无力病例也有成功报告。
- 嵌合自身抗体受体T细胞在体外和体内条件下选择性靶向自身反应性抗N-甲基-D-天冬氨酸B细胞,为人研究和应用于其他神经元或胶质抗体相关自身免疫性脑炎提供基础。
局限性
- 胶质母细胞瘤的首次人体试验未取得显著成功或仅部分患者有限成功。
- 多发性硬化中CAR T细胞疗法的疗效仅在动物模型中证实,尚需更大规模人类研究 corroborate。
- 视神经脊髓炎谱系疾病的结果需更大患者群体研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field of neurology, particularly for primary brain tumors and autoimmune neurological disorders. OBSERVATIONS: CAR T-cell therapy for glioblastoma is promising; however, first-in-human trials did not yield significant success or showed only limited success in a subset of patients. To date, the efficacy of CAR T-cell therapies has been demonstrated in animal models of multiple sclerosis, but larger human studies to corroborate the efficacy remain pending. CAR T cells showed efficacy in treatment of patients with relapsed or refractory aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorders. Further studies with larger patient populations are needed to confirm these results. Success was reported also for treatment of cases with generalized myasthenia gravis using CAR T cells. Chimeric autoantibody receptor T cells, representing a modified form of CAR T cells directed against autoreactive B cells secreting autoantibodies, were used to selectively target autoreactive anti-N-methyl-d-aspartate B cells under in vitro and in vivo conditions, providing the basis for human studies and application to other types of autoimmune encephalitis associated with neuronal or glial antibodies. CONCLUSIONS AND RELEVANCE: CAR T cells herald a new era in the therapeutic landscape of neurological disorders. While their application in solid tumors, such as glioblastoma, has not universally yielded robust success, emerging innovative strategies show promise, and there is optimism for their effectiveness in certain autoimmune neurological disorders.
引用
- Ismail FS, Gallus M, Meuth SG, et al. Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review. JAMA Neurol. 2025. PMID: 39585688. doi:10.1001/jamaneurol.2024.3818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。